ESPR Esperion Therapeutics, Inc.
Research report · from SEC EDGAR · close 2026-07-10
$3.18 -0.3%
$818.6M mkt cap
executive summary
Esperion Therapeutics, Inc. (ESPR) is a $818.6M company. Revenue is $403.1M (+21.3% y/y) at a -6% net margin. It is not yet profitable. Our health score is D (53/100). 3 red flags on file. It funds itself; low dilution risk.
Revenue (FY)
$403.1M
+21.3% y/y
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-2.53).
⚠Active dilution shelf
An effective S-3 shelf with 2 prospectus filing(s) in 12 months — shares may be getting sold into the market.
⚠One-sided insider selling
7 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 7
Cash & ST investments
$156.2M
Operating cash flow
-$13.1M
Dilution shelf
active shelf
FILINGShareholder vote results
8-K filed 2026-07-08
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-10 by stocktools.ai.